argenx SE (ARGX) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Amsterdam, Netherlands. Der aktuelle CEO ist Timothy Van Hauwermeiren.
ARGX hat IPO-Datum 2017-05-18, 1,599 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $51.26B.
Argenx SE is a biotechnology company headquartered in Amsterdam, Netherlands, focused on developing innovative therapies for autoimmune diseases across the United States, Europe, Japan, China, and other global markets. The company's lead product, efgartigimod, targets multiple autoimmune conditions including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris, with a pipeline of additional candidates such as empasiprubart and ARGX-119 addressing conditions like motor neuropathy and amyotrophic lateral sclerosis. Argenx has established strategic partnerships with major pharmaceutical companies including AbbVie, Zai Lab, and LEO Pharma, along with collaborations with leading academic institutions and biotech firms to advance its research and development efforts. The company leverages proprietary platforms and technologies, including its SIMPLE ANTIBODY technology, to discover and develop novel therapeutic antibodies with applications in immunology and oncology.
